Celadon Pharmaceuticals Plc

As of December 31, 2023, Celadon Pharmaceuticals Plc has 64.21M shares outstanding.

These figures are as of December 31, 2023. The EV/Sales ratio of 46.41 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of December 31, 2023, Celadon Pharmaceuticals Plc maintains a current ratio of 2.62, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 148.29, indicating elevated leverage, while an interest coverage ratio of -10.39 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2023. Return on assets (ROA) is negative at -63.55, reflecting losses generated across the asset base.

As of the close on July 28, 2025, Celadon Pharmaceuticals Plc's stock has declined approximately 99.79% over the past 52 weeks. The 50-day moving average sits at 6.35, while the 200-day moving average is 13.86.

Over the twelve months ended December 31, 2023, Celadon Pharmaceuticals Plc posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -8,288.00 and net profit margin of -9,520.00 provide insight into operational efficiency.

As of December 31, 2023, Celadon Pharmaceuticals Plc has an Altman Z-Score of -6.93, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.